Lehrstuhl für Geburtshilfe und Frauenheilkunde

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry (2024) Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching P, Ettl J, et al. Journal article CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs (2024) Schneeweiss A, Brucker SY, Hübner H, Volmer LL, Hack C, Seitz K, Rübner M, et al. Journal article, Review article Clinical and Surgical Evaluation of Sentinel Node Biopsy in Patients with Early-Stage Endometrial Cancer and Atypical Hyperplasia (2024) Pöschke P, Gaß P, Krückel A, Keller K, Erber R, Hartmann A, Beckmann M, Emons J Journal article Functional Heterogeneity of Umbilical Cord Blood Monocyte-Derived Dendritic Cells (2024) Schweiger P, Hamann L, Strobel J, Weisbach V, Wandersee A, Christ J, Kehl S, et al. Journal article Power-MF: Robust fetal QRS detection from non-invasive fetal electrocardiogram recordings (2024) Jäger K, Nissen M, Rahm S, Titzmann A, Fasching P, Beilner J, Eskofier B, Leutheuser H Journal article PROTAC Drugs in Cancer Care (2024) Fasching P Journal article Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG) (2024) Stübs F, Beckmann M, Dannecker C, Follmann M, Nothacker M, Schnürch HG, Woelber L, Wesselmann S Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024) Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al. Journal article Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer (2024) Gaß P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, et al. Journal article